Daniel Renois, MD
Family Medicine · Alexandria, LANPI 1316043730
Payments from drug & device makers
Across 214 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$714
- Novo Nordisk$526
- AstraZeneca$286
- Pfizer$278
- Lilly USA, LLC$165
- Otsuka America Pharmaceutical, Inc.$161
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,392100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $714 |
| Novo Nordisk | 40 | $526 |
| AstraZeneca | 17 | $286 |
| Pfizer | 26 | $278 |
| Lilly USA, LLC | 11 | $165 |
| Otsuka America Pharmaceutical, Inc. | 8 | $161 |
| Melinta Therapeutics, LLC | 2 | $128 |
| Amgen | 7 | $101 |
| Organogenesis Inc. | 1 | $100 |
| Sanofi-aventis U.S. LLC | 6 | $79 |
| Abbott | 5 | $74 |
| Fresenius USA Marketing, Inc. | 4 | $72 |
| Axsome Therapeutics, Inc. | 4 | $71 |
| Sunovion Pharmaceuticals Inc. | 5 | $70 |
| Dexcom, Inc. | 3 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Boehringer Ingelheim | 4 | $52 |
| Amarin Pharma, Inc. | 3 | $41 |
| Novartis | 3 | $41 |
| GSK | 2 | $32 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Smith+Nephew | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orbactiv$114
- Apligraf$100
- Dermagraft$100
- Puraply/Affinity/NuTech$100
How this compares
$3,392 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $133,700 |
| TrulicityDulaglutide | 109 | $117,096 |
| OzempicSemaglutide | 82 | $97,905 |
| MounjaroTirzepatide | 81 | $88,203 |
| LinzessLinaclotide | 96 | $72,295 |
| JardianceEmpagliflozin | 116 | $65,883 |
| FarxigaDapagliflozin Propanediol | 78 | $43,013 |
| JanuviaSitagliptin Phosphate | 51 | $32,795 |
| EntrestoSacubitril/Valsartan | 90 | $30,896 |
| GemtesaVibegron | 113 | $30,169 |
| SavellaMilnacipran Hcl | 17 | $27,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $26,912 |
| TivicayDolutegravir Sodium | 13 | $26,610 |
| XareltoRivaroxaban | 63 | $26,106 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $25,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $165 | $205,300190 claims |
| PfizerEliquis | $278 | $133,700311 claims |
| AbbVieLinzess, Savella, Vraylar, Restasis | $714 | $117,919142 claims |
| Novo NordiskOzempic | $526 | $97,90582 claims |
| Boehringer IngelheimJardiance | $52 | $65,883116 claims |
| AstraZenecaFarxiga | $286 | $43,01378 claims |
| NovartisEntresto | $41 | $30,89690 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $30,169113 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Multaq | $79 | $27,89929 claims |
| GSKTrelegy Ellipta | $32 | $26,91239 claims |
| Johnson & JohnsonXarelto | $24 | $26,10663 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $63 | $20,97913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Alexandria
- Michael ScrepetisAlexandria$27K
- Gregory BevelsAlexandria$24K
- Kenneth BrownAlexandria$17K
- Gregory BrianAlexandria$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.